Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Bipolar Disorder | 133 | 2023 | 5092 | 11.580 |
Why?
|
Antidepressive Agents | 57 | 2022 | 2897 | 5.830 |
Why?
|
Antimanic Agents | 29 | 2021 | 520 | 5.060 |
Why?
|
Antipsychotic Agents | 46 | 2022 | 3067 | 4.260 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 28 | 2022 | 1988 | 3.330 |
Why?
|
Obsessive-Compulsive Disorder | 12 | 2017 | 1491 | 2.740 |
Why?
|
Psychiatric Status Rating Scales | 43 | 2020 | 6019 | 2.400 |
Why?
|
Psychopharmacology | 6 | 2022 | 148 | 2.260 |
Why?
|
Depressive Disorder | 24 | 2020 | 3728 | 2.020 |
Why?
|
Depressive Disorder, Major | 26 | 2020 | 4761 | 2.010 |
Why?
|
Mood Disorders | 11 | 2014 | 1127 | 1.980 |
Why?
|
Lithium Compounds | 8 | 2024 | 223 | 1.890 |
Why?
|
Valproic Acid | 15 | 2021 | 443 | 1.780 |
Why?
|
Psychiatry | 12 | 2022 | 1693 | 1.720 |
Why?
|
Affect | 10 | 2020 | 1486 | 1.630 |
Why?
|
Citalopram | 3 | 2021 | 402 | 1.610 |
Why?
|
Borderline Personality Disorder | 6 | 2015 | 768 | 1.540 |
Why?
|
Anticonvulsants | 23 | 2021 | 1906 | 1.350 |
Why?
|
Psychotropic Drugs | 6 | 2015 | 888 | 1.160 |
Why?
|
Lithium | 14 | 2020 | 596 | 1.150 |
Why?
|
Psychomotor Agitation | 4 | 2019 | 305 | 1.020 |
Why?
|
Piperazines | 7 | 2015 | 2523 | 1.010 |
Why?
|
Risperidone | 9 | 2004 | 381 | 0.950 |
Why?
|
Existentialism | 5 | 2018 | 39 | 0.930 |
Why?
|
Benzodiazepines | 8 | 2015 | 1132 | 0.920 |
Why?
|
Thiazoles | 5 | 2015 | 1517 | 0.910 |
Why?
|
Antidepressive Agents, Second-Generation | 5 | 2021 | 489 | 0.900 |
Why?
|
Drug Therapy, Combination | 33 | 2021 | 6312 | 0.870 |
Why?
|
Psychopathology | 2 | 2019 | 432 | 0.860 |
Why?
|
Lithium Carbonate | 7 | 2010 | 179 | 0.860 |
Why?
|
Psychotherapy | 9 | 2015 | 1647 | 0.840 |
Why?
|
Triazines | 5 | 2014 | 311 | 0.820 |
Why?
|
Mental Disorders | 13 | 2020 | 6845 | 0.810 |
Why?
|
International Classification of Diseases | 5 | 2014 | 909 | 0.750 |
Why?
|
Clomipramine | 2 | 2017 | 54 | 0.710 |
Why?
|
Randomized Controlled Trials as Topic | 17 | 2024 | 10212 | 0.700 |
Why?
|
Carbamazepine | 5 | 2014 | 224 | 0.680 |
Why?
|
Psychological Theory | 2 | 2012 | 175 | 0.670 |
Why?
|
Cyclohexanecarboxylic Acids | 4 | 2001 | 140 | 0.670 |
Why?
|
Humans | 191 | 2024 | 761572 | 0.660 |
Why?
|
Psychotic Disorders | 12 | 2020 | 3223 | 0.660 |
Why?
|
Amines | 4 | 2001 | 281 | 0.630 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 4 | 2023 | 3708 | 0.620 |
Why?
|
Comorbidity | 18 | 2015 | 10508 | 0.610 |
Why?
|
Awareness | 7 | 2012 | 648 | 0.600 |
Why?
|
Galantamine | 2 | 2009 | 33 | 0.590 |
Why?
|
Advisory Committees | 5 | 2013 | 787 | 0.580 |
Why?
|
Basal Ganglia Diseases | 5 | 2006 | 145 | 0.570 |
Why?
|
Treatment Outcome | 59 | 2021 | 64684 | 0.570 |
Why?
|
Suicide | 5 | 2024 | 1601 | 0.560 |
Why?
|
Diagnostic Errors | 6 | 2011 | 1265 | 0.550 |
Why?
|
Isoxazoles | 3 | 2007 | 232 | 0.540 |
Why?
|
Sertraline | 2 | 2014 | 209 | 0.520 |
Why?
|
Pirenzepine | 3 | 2000 | 116 | 0.520 |
Why?
|
Acetates | 4 | 2001 | 321 | 0.510 |
Why?
|
Temperament | 2 | 2023 | 297 | 0.510 |
Why?
|
Depression | 8 | 2021 | 8124 | 0.510 |
Why?
|
Carcinogenicity Tests | 1 | 2015 | 38 | 0.500 |
Why?
|
Meta-Analysis as Topic | 3 | 2024 | 1380 | 0.490 |
Why?
|
gamma-Aminobutyric Acid | 5 | 2001 | 1141 | 0.480 |
Why?
|
Quinolones | 2 | 2008 | 378 | 0.470 |
Why?
|
Depression, Postpartum | 2 | 2017 | 346 | 0.450 |
Why?
|
Research Design | 12 | 2020 | 6180 | 0.450 |
Why?
|
Terminology as Topic | 4 | 2017 | 1530 | 0.440 |
Why?
|
Adult | 79 | 2023 | 221203 | 0.440 |
Why?
|
Double-Blind Method | 15 | 2021 | 12341 | 0.440 |
Why?
|
Emergency Services, Psychiatric | 2 | 2006 | 67 | 0.430 |
Why?
|
Trace Elements | 1 | 2014 | 195 | 0.410 |
Why?
|
Behavioral Symptoms | 1 | 2014 | 186 | 0.400 |
Why?
|
Dibenzothiazepines | 3 | 2001 | 102 | 0.390 |
Why?
|
Antidepressive Agents, Tricyclic | 3 | 2007 | 432 | 0.390 |
Why?
|
Clozapine | 4 | 2000 | 504 | 0.390 |
Why?
|
Acute Disease | 12 | 2021 | 7237 | 0.380 |
Why?
|
Dyskinesia, Drug-Induced | 2 | 2002 | 165 | 0.380 |
Why?
|
Affective Symptoms | 2 | 2011 | 417 | 0.380 |
Why?
|
Drug Prescriptions | 2 | 2014 | 1670 | 0.370 |
Why?
|
Drug Administration Schedule | 12 | 2021 | 4853 | 0.370 |
Why?
|
Neuropsychological Tests | 5 | 2018 | 7054 | 0.370 |
Why?
|
Male | 83 | 2021 | 360842 | 0.360 |
Why?
|
Fructose | 3 | 2001 | 288 | 0.360 |
Why?
|
Lithium Chloride | 1 | 2010 | 82 | 0.350 |
Why?
|
Second Messenger Systems | 2 | 2022 | 202 | 0.350 |
Why?
|
Female | 83 | 2021 | 392686 | 0.340 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2015 | 1334 | 0.340 |
Why?
|
Diagnosis, Differential | 15 | 2017 | 12975 | 0.340 |
Why?
|
Evidence-Based Medicine | 3 | 2011 | 3688 | 0.330 |
Why?
|
Substance-Related Disorders | 4 | 2013 | 4420 | 0.320 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 1 | 2010 | 324 | 0.320 |
Why?
|
Publication Bias | 1 | 2009 | 160 | 0.310 |
Why?
|
Hippocratic Oath | 1 | 2008 | 16 | 0.300 |
Why?
|
Bibliometrics | 1 | 2012 | 352 | 0.300 |
Why?
|
Nootropic Agents | 1 | 2009 | 157 | 0.300 |
Why?
|
Cyclothymic Disorder | 2 | 2023 | 42 | 0.300 |
Why?
|
Middle Aged | 50 | 2021 | 220920 | 0.290 |
Why?
|
Societies, Medical | 3 | 2009 | 3905 | 0.290 |
Why?
|
Neuroprotective Agents | 1 | 2014 | 957 | 0.290 |
Why?
|
Recurrence | 11 | 2015 | 8466 | 0.280 |
Why?
|
Central Nervous System Stimulants | 3 | 2015 | 1177 | 0.280 |
Why?
|
Publishing | 2 | 2012 | 833 | 0.270 |
Why?
|
Philosophy, Medical | 1 | 2007 | 79 | 0.270 |
Why?
|
Jaundice, Neonatal | 1 | 2007 | 71 | 0.270 |
Why?
|
Placebo Effect | 2 | 2021 | 518 | 0.270 |
Why?
|
United States Food and Drug Administration | 1 | 2015 | 1664 | 0.270 |
Why?
|
Pharmacogenetics | 1 | 2010 | 675 | 0.270 |
Why?
|
Peer Review, Research | 1 | 2009 | 340 | 0.260 |
Why?
|
Secondary Prevention | 7 | 2011 | 1475 | 0.260 |
Why?
|
Time Perception | 1 | 2006 | 87 | 0.260 |
Why?
|
Observation | 2 | 2006 | 310 | 0.250 |
Why?
|
Prevalence | 9 | 2023 | 15732 | 0.250 |
Why?
|
Cognition Disorders | 3 | 2009 | 3980 | 0.240 |
Why?
|
Predictive Value of Tests | 6 | 2020 | 15266 | 0.240 |
Why?
|
Psychoanalytic Therapy | 2 | 2004 | 228 | 0.240 |
Why?
|
Internal Medicine | 1 | 2012 | 1051 | 0.240 |
Why?
|
Biomedical Research | 2 | 2012 | 3429 | 0.230 |
Why?
|
Cholinesterase Inhibitors | 1 | 2006 | 242 | 0.230 |
Why?
|
Follow-Up Studies | 14 | 2021 | 39107 | 0.220 |
Why?
|
Severity of Illness Index | 14 | 2019 | 15843 | 0.220 |
Why?
|
History, 20th Century | 5 | 2017 | 2767 | 0.210 |
Why?
|
Disease Management | 1 | 2014 | 2508 | 0.210 |
Why?
|
Cultural Diversity | 1 | 2007 | 369 | 0.210 |
Why?
|
Personality Inventory | 3 | 2023 | 1019 | 0.210 |
Why?
|
Age of Onset | 6 | 2014 | 3306 | 0.210 |
Why?
|
Irritable Mood | 4 | 2014 | 194 | 0.200 |
Why?
|
Placebos | 4 | 2020 | 1667 | 0.190 |
Why?
|
Adolescent | 18 | 2021 | 88324 | 0.190 |
Why?
|
Poverty | 1 | 2013 | 2698 | 0.190 |
Why?
|
Mind-Body Relations, Metaphysical | 1 | 2001 | 36 | 0.180 |
Why?
|
Urinary Tract Infections | 1 | 2007 | 802 | 0.180 |
Why?
|
Paroxetine | 2 | 1998 | 182 | 0.180 |
Why?
|
Akathisia, Drug-Induced | 3 | 2008 | 67 | 0.170 |
Why?
|
Ambulatory Care | 8 | 2008 | 2775 | 0.170 |
Why?
|
Aftercare | 1 | 2006 | 914 | 0.170 |
Why?
|
Intention to Treat Analysis | 1 | 2021 | 413 | 0.170 |
Why?
|
Young Adult | 10 | 2021 | 59255 | 0.170 |
Why?
|
Diagnosis, Dual (Psychiatry) | 2 | 2013 | 303 | 0.170 |
Why?
|
Dementia | 1 | 2014 | 2689 | 0.170 |
Why?
|
Kindling, Neurologic | 1 | 1999 | 24 | 0.160 |
Why?
|
Thioridazine | 1 | 1998 | 33 | 0.160 |
Why?
|
Community Mental Health Services | 3 | 2011 | 392 | 0.150 |
Why?
|
Polypharmacy | 1 | 2021 | 306 | 0.150 |
Why?
|
Nortriptyline | 1 | 1998 | 79 | 0.150 |
Why?
|
Serotonin Antagonists | 1 | 1999 | 145 | 0.150 |
Why?
|
Long-Term Care | 3 | 2008 | 633 | 0.150 |
Why?
|
Reproducibility of Results | 7 | 2020 | 20099 | 0.150 |
Why?
|
Primary Health Care | 2 | 2020 | 4686 | 0.150 |
Why?
|
Seasonal Affective Disorder | 1 | 1997 | 49 | 0.150 |
Why?
|
Dose-Response Relationship, Drug | 7 | 2008 | 10766 | 0.150 |
Why?
|
Medical Records | 4 | 2006 | 1408 | 0.150 |
Why?
|
Fluvoxamine | 1 | 2017 | 78 | 0.150 |
Why?
|
Humanism | 1 | 2018 | 86 | 0.140 |
Why?
|
Personality | 2 | 2012 | 554 | 0.140 |
Why?
|
Ecosystem | 1 | 2021 | 490 | 0.140 |
Why?
|
Endpoint Determination | 2 | 2011 | 590 | 0.140 |
Why?
|
Mental Health Services | 2 | 2008 | 1730 | 0.140 |
Why?
|
Time Factors | 6 | 2020 | 39970 | 0.130 |
Why?
|
Mass Screening | 3 | 2020 | 5428 | 0.130 |
Why?
|
Electric Injuries | 1 | 1995 | 24 | 0.130 |
Why?
|
Adaptive Immunity | 1 | 2020 | 726 | 0.120 |
Why?
|
Factor Analysis, Statistical | 1 | 2018 | 999 | 0.120 |
Why?
|
Retrospective Studies | 21 | 2014 | 80646 | 0.120 |
Why?
|
Emotions | 1 | 2006 | 2739 | 0.120 |
Why?
|
Attitude to Health | 3 | 2010 | 2025 | 0.120 |
Why?
|
Paresthesia | 1 | 1995 | 162 | 0.120 |
Why?
|
GTP-Binding Proteins | 1 | 1999 | 951 | 0.120 |
Why?
|
Drug Discovery | 1 | 2022 | 1051 | 0.120 |
Why?
|
Psychometrics | 3 | 2018 | 3065 | 0.110 |
Why?
|
South America | 1 | 2014 | 179 | 0.110 |
Why?
|
Nausea | 2 | 2008 | 679 | 0.110 |
Why?
|
ROC Curve | 3 | 2018 | 3579 | 0.110 |
Why?
|
Cross-Sectional Studies | 5 | 2020 | 26127 | 0.110 |
Why?
|
Regression Analysis | 4 | 2008 | 6344 | 0.110 |
Why?
|
Prospective Studies | 9 | 2013 | 54426 | 0.110 |
Why?
|
Practice Guidelines as Topic | 2 | 2008 | 7391 | 0.110 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2865 | 0.110 |
Why?
|
Anti-Anxiety Agents | 1 | 2015 | 397 | 0.100 |
Why?
|
Asia | 1 | 2014 | 619 | 0.100 |
Why?
|
Sensitivity and Specificity | 5 | 2020 | 14666 | 0.100 |
Why?
|
Tunisia | 1 | 2012 | 36 | 0.100 |
Why?
|
Edema | 1 | 1996 | 766 | 0.100 |
Why?
|
History, Medieval | 1 | 2012 | 62 | 0.100 |
Why?
|
Epidemiologic Studies | 2 | 2014 | 675 | 0.100 |
Why?
|
Iraq | 1 | 2012 | 92 | 0.100 |
Why?
|
Drug Utilization | 3 | 2009 | 1188 | 0.100 |
Why?
|
Pilot Projects | 4 | 2009 | 8633 | 0.100 |
Why?
|
Europe | 2 | 2014 | 3422 | 0.100 |
Why?
|
Observer Variation | 1 | 2018 | 2606 | 0.100 |
Why?
|
Behavioral Research | 1 | 2011 | 52 | 0.090 |
Why?
|
Cholesterol | 1 | 2000 | 2904 | 0.090 |
Why?
|
History, 21st Century | 1 | 2017 | 1567 | 0.090 |
Why?
|
Glucocorticoids | 1 | 2020 | 2161 | 0.090 |
Why?
|
MEDLINE | 1 | 2010 | 119 | 0.090 |
Why?
|
Aged | 15 | 2020 | 169310 | 0.090 |
Why?
|
Concept Formation | 1 | 2011 | 161 | 0.090 |
Why?
|
North America | 1 | 2014 | 1276 | 0.090 |
Why?
|
Syndrome | 2 | 2009 | 3267 | 0.090 |
Why?
|
Sex Distribution | 2 | 2007 | 2281 | 0.090 |
Why?
|
Interview, Psychological | 1 | 2013 | 809 | 0.090 |
Why?
|
Triazoles | 1 | 1995 | 903 | 0.090 |
Why?
|
Hospitalization | 6 | 2013 | 10721 | 0.090 |
Why?
|
Weight Gain | 3 | 2006 | 2348 | 0.090 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2020 | 1413 | 0.080 |
Why?
|
Students | 1 | 2020 | 1741 | 0.080 |
Why?
|
Cognition | 2 | 2004 | 6992 | 0.080 |
Why?
|
Age Factors | 4 | 2015 | 18398 | 0.080 |
Why?
|
Cross-Over Studies | 1 | 2015 | 2079 | 0.080 |
Why?
|
Motivation | 1 | 1999 | 2006 | 0.080 |
Why?
|
United States | 6 | 2020 | 72335 | 0.080 |
Why?
|
Anxiety Disorders | 1 | 2000 | 2720 | 0.080 |
Why?
|
Schizophrenic Psychology | 1 | 1995 | 1647 | 0.080 |
Why?
|
Self Concept | 2 | 2006 | 1045 | 0.070 |
Why?
|
Wounds and Injuries | 1 | 2020 | 2491 | 0.070 |
Why?
|
Tranylcypromine | 1 | 2007 | 30 | 0.070 |
Why?
|
Greece | 1 | 2008 | 340 | 0.070 |
Why?
|
Frustration | 1 | 2007 | 22 | 0.070 |
Why?
|
Mianserin | 1 | 2007 | 51 | 0.070 |
Why?
|
Reality Testing | 1 | 2006 | 24 | 0.070 |
Why?
|
Biological Psychiatry | 1 | 2007 | 26 | 0.070 |
Why?
|
Patient Selection | 2 | 2011 | 4244 | 0.070 |
Why?
|
Lorazepam | 1 | 2008 | 154 | 0.070 |
Why?
|
Perceptual Distortion | 1 | 2006 | 36 | 0.070 |
Why?
|
Freedom | 1 | 2007 | 69 | 0.070 |
Why?
|
Cyclohexanols | 1 | 2007 | 126 | 0.070 |
Why?
|
Psychoanalytic Theory | 1 | 2007 | 138 | 0.070 |
Why?
|
Schizophrenia | 2 | 2015 | 6937 | 0.070 |
Why?
|
Models, Psychological | 2 | 2014 | 829 | 0.070 |
Why?
|
Parkinson Disease, Secondary | 1 | 2006 | 122 | 0.060 |
Why?
|
Risk Factors | 8 | 2013 | 74213 | 0.060 |
Why?
|
Empathy | 1 | 2010 | 473 | 0.060 |
Why?
|
Dyskinesias | 1 | 2006 | 79 | 0.060 |
Why?
|
History, 19th Century | 1 | 2008 | 720 | 0.060 |
Why?
|
Spirituality | 1 | 2010 | 425 | 0.060 |
Why?
|
Safety | 1 | 2010 | 1150 | 0.060 |
Why?
|
Child Health Services | 1 | 2011 | 646 | 0.060 |
Why?
|
September 11 Terrorist Attacks | 1 | 2006 | 105 | 0.060 |
Why?
|
Internal-External Control | 1 | 2006 | 358 | 0.060 |
Why?
|
Blood Chemical Analysis | 1 | 2007 | 437 | 0.060 |
Why?
|
Bilirubin | 1 | 2007 | 436 | 0.060 |
Why?
|
Clinical Trials as Topic | 4 | 2004 | 8002 | 0.060 |
Why?
|
Anxiety | 1 | 2020 | 4573 | 0.060 |
Why?
|
Case-Control Studies | 3 | 2020 | 22176 | 0.060 |
Why?
|
Urinalysis | 1 | 2007 | 368 | 0.060 |
Why?
|
Patient Dropouts | 2 | 2004 | 412 | 0.060 |
Why?
|
Demography | 2 | 2007 | 1648 | 0.060 |
Why?
|
Child | 5 | 2015 | 80156 | 0.060 |
Why?
|
Science | 1 | 2007 | 239 | 0.060 |
Why?
|
Delayed-Action Preparations | 1 | 2007 | 962 | 0.060 |
Why?
|
Periodicity | 1 | 2005 | 348 | 0.060 |
Why?
|
Neoplasms | 1 | 2013 | 22173 | 0.060 |
Why?
|
Attitude to Death | 1 | 2007 | 400 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5336 | 0.050 |
Why?
|
Sex Factors | 4 | 2008 | 10553 | 0.050 |
Why?
|
False Negative Reactions | 1 | 2004 | 573 | 0.050 |
Why?
|
Analysis of Variance | 1 | 2012 | 6228 | 0.050 |
Why?
|
Vomiting | 1 | 2006 | 651 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 3052 | 0.050 |
Why?
|
Task Performance and Analysis | 1 | 2007 | 763 | 0.050 |
Why?
|
Prognosis | 3 | 2011 | 29629 | 0.050 |
Why?
|
Reaction Time | 1 | 2009 | 2089 | 0.050 |
Why?
|
Dystonia | 1 | 2006 | 370 | 0.050 |
Why?
|
Drug Resistance | 1 | 2008 | 1596 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
Electroconvulsive Therapy | 1 | 2008 | 500 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
Canada | 1 | 2008 | 2122 | 0.050 |
Why?
|
Resilience, Psychological | 1 | 2010 | 788 | 0.050 |
Why?
|
Appointments and Schedules | 1 | 2006 | 443 | 0.050 |
Why?
|
Disclosure | 1 | 2007 | 748 | 0.050 |
Why?
|
Probability | 1 | 2007 | 2477 | 0.050 |
Why?
|
Drug Monitoring | 1 | 2007 | 962 | 0.050 |
Why?
|
Impulsive Behavior | 1 | 2003 | 346 | 0.050 |
Why?
|
Attention Deficit and Disruptive Behavior Disorders | 1 | 2003 | 306 | 0.050 |
Why?
|
Haloperidol | 1 | 2002 | 389 | 0.050 |
Why?
|
Drug Tolerance | 1 | 2002 | 367 | 0.040 |
Why?
|
Longitudinal Studies | 4 | 2010 | 14607 | 0.040 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2001 | 186 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8656 | 0.040 |
Why?
|
Survival Analysis | 2 | 2010 | 10090 | 0.040 |
Why?
|
Switzerland | 1 | 2001 | 324 | 0.040 |
Why?
|
India | 1 | 2007 | 2348 | 0.040 |
Why?
|
Polymorphism, Genetic | 1 | 2010 | 4243 | 0.040 |
Why?
|
Public Health | 1 | 2013 | 2669 | 0.040 |
Why?
|
Professional-Patient Relations | 1 | 2005 | 726 | 0.040 |
Why?
|
Memory | 1 | 2009 | 2193 | 0.040 |
Why?
|
Economics, Pharmaceutical | 1 | 1999 | 87 | 0.040 |
Why?
|
Cost of Illness | 1 | 2009 | 1936 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2020 | 385 | 0.040 |
Why?
|
Dyslipidemias | 1 | 2006 | 868 | 0.040 |
Why?
|
Risk Assessment | 2 | 2011 | 23996 | 0.040 |
Why?
|
Cohort Studies | 4 | 2007 | 41493 | 0.040 |
Why?
|
Virginia | 1 | 1998 | 116 | 0.040 |
Why?
|
Defense Mechanisms | 1 | 1999 | 180 | 0.040 |
Why?
|
Fluoxetine | 1 | 2002 | 733 | 0.040 |
Why?
|
Outpatients | 1 | 2006 | 1597 | 0.040 |
Why?
|
Logistic Models | 1 | 2013 | 13255 | 0.040 |
Why?
|
Personality Assessment | 1 | 2000 | 650 | 0.040 |
Why?
|
Dopamine Agonists | 1 | 2000 | 352 | 0.040 |
Why?
|
Bayes Theorem | 1 | 2006 | 2330 | 0.040 |
Why?
|
Remote Consultation | 1 | 2020 | 237 | 0.040 |
Why?
|
Delusions | 1 | 2000 | 298 | 0.040 |
Why?
|
Culture | 2 | 2008 | 623 | 0.040 |
Why?
|
Videotape Recording | 1 | 1998 | 337 | 0.040 |
Why?
|
Hallucinations | 1 | 2000 | 366 | 0.030 |
Why?
|
Chronic Disease | 1 | 2012 | 9319 | 0.030 |
Why?
|
Research | 1 | 2005 | 1982 | 0.030 |
Why?
|
Acetylcholine | 1 | 1999 | 629 | 0.030 |
Why?
|
Pedigree | 1 | 2004 | 4542 | 0.030 |
Why?
|
Public Sector | 1 | 1998 | 267 | 0.030 |
Why?
|
STAT3 Transcription Factor | 1 | 2020 | 871 | 0.030 |
Why?
|
Phenotype | 2 | 2020 | 16592 | 0.030 |
Why?
|
Hostility | 1 | 1996 | 183 | 0.030 |
Why?
|
Combined Modality Therapy | 2 | 2007 | 8528 | 0.030 |
Why?
|
Stress Disorders, Post-Traumatic | 3 | 2006 | 4575 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2006 | 2759 | 0.030 |
Why?
|
Commitment of Mentally Ill | 1 | 1995 | 94 | 0.030 |
Why?
|
Circadian Rhythm | 1 | 2006 | 2576 | 0.030 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 1998 | 1541 | 0.030 |
Why?
|
Phototherapy | 1 | 1997 | 368 | 0.030 |
Why?
|
Developing Countries | 1 | 2007 | 2885 | 0.030 |
Why?
|
Protein Kinase C | 1 | 1999 | 1202 | 0.030 |
Why?
|
Anger | 1 | 1996 | 406 | 0.030 |
Why?
|
Data Interpretation, Statistical | 1 | 2003 | 2691 | 0.030 |
Why?
|
Health Status | 2 | 2004 | 4077 | 0.030 |
Why?
|
Patient Education as Topic | 1 | 2004 | 2319 | 0.030 |
Why?
|
Patient Readmission | 2 | 1998 | 3271 | 0.030 |
Why?
|
Fatigue | 1 | 2020 | 1552 | 0.030 |
Why?
|
Massachusetts | 1 | 2006 | 8830 | 0.030 |
Why?
|
Referral and Consultation | 1 | 2006 | 3600 | 0.030 |
Why?
|
Patient Discharge | 1 | 2006 | 3443 | 0.030 |
Why?
|
Cost Savings | 1 | 1998 | 913 | 0.030 |
Why?
|
Family | 1 | 2003 | 3194 | 0.030 |
Why?
|
Hospitals, Psychiatric | 1 | 1994 | 321 | 0.030 |
Why?
|
Epilepsy, Temporal Lobe | 1 | 1996 | 389 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2012 | 18253 | 0.030 |
Why?
|
Data Collection | 1 | 2001 | 3322 | 0.030 |
Why?
|
Consensus | 2 | 2013 | 3123 | 0.020 |
Why?
|
Aggression | 1 | 1996 | 750 | 0.020 |
Why?
|
Risk | 1 | 2003 | 9610 | 0.020 |
Why?
|
Cell Communication | 1 | 1999 | 1657 | 0.020 |
Why?
|
Genetic Markers | 1 | 1998 | 2601 | 0.020 |
Why?
|
Animals | 2 | 2015 | 168467 | 0.020 |
Why?
|
Registries | 1 | 2007 | 8224 | 0.020 |
Why?
|
Mental Recall | 1 | 1996 | 1221 | 0.020 |
Why?
|
Visual Perception | 1 | 1998 | 1389 | 0.020 |
Why?
|
Weight Loss | 1 | 2001 | 2684 | 0.020 |
Why?
|
Frontal Lobe | 1 | 1996 | 1420 | 0.020 |
Why?
|
Delphi Technique | 1 | 2013 | 846 | 0.020 |
Why?
|
Body Weight | 1 | 2000 | 4618 | 0.020 |
Why?
|
Synapses | 1 | 1999 | 1769 | 0.020 |
Why?
|
Phosphorylation | 1 | 2020 | 8321 | 0.020 |
Why?
|
Patient Admission | 1 | 1995 | 1367 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2006 | 5841 | 0.020 |
Why?
|
Life Change Events | 2 | 2006 | 952 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2007 | 26198 | 0.020 |
Why?
|
Iran | 1 | 2009 | 737 | 0.020 |
Why?
|
Drug Administration Routes | 1 | 2005 | 150 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 1998 | 5492 | 0.020 |
Why?
|
Pain | 1 | 2020 | 5073 | 0.020 |
Why?
|
Patient Compliance | 1 | 1994 | 2690 | 0.010 |
Why?
|
Morbidity | 1 | 2009 | 1750 | 0.010 |
Why?
|
Stress, Psychological | 1 | 1999 | 4481 | 0.010 |
Why?
|
Mass Media | 1 | 2006 | 303 | 0.010 |
Why?
|
Brief Psychiatric Rating Scale | 1 | 2002 | 109 | 0.010 |
Why?
|
Body Mass Index | 1 | 2000 | 12954 | 0.010 |
Why?
|
Antiparkinson Agents | 1 | 2002 | 184 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2008 | 1386 | 0.010 |
Why?
|
Length of Stay | 1 | 1994 | 6426 | 0.010 |
Why?
|
Suicide, Attempted | 1 | 2009 | 1402 | 0.010 |
Why?
|
Child, Preschool | 1 | 2003 | 42230 | 0.010 |
Why?
|
Benzothiazoles | 1 | 2000 | 247 | 0.010 |
Why?
|
Algorithms | 1 | 2000 | 14032 | 0.010 |
Why?
|
Treatment Refusal | 1 | 2002 | 429 | 0.010 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2008 | 1081 | 0.010 |
Why?
|
Alzheimer Disease | 1 | 1999 | 8601 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2007 | 6484 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2009 | 7827 | 0.010 |
Why?
|
Propranolol | 1 | 1996 | 489 | 0.010 |
Why?
|
Odds Ratio | 1 | 2005 | 9646 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2007 | 12463 | 0.010 |
Why?
|
Neurologic Examination | 1 | 1996 | 916 | 0.010 |
Why?
|